Please ensure Javascript is enabled for purposes of website accessibility

What You'll Want to Know About Centene's Terrific Q3 Results

By Keith Speights - Updated Oct 22, 2019 at 4:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Great revenue and earnings growth made investors happy with the health insurer's latest performance.

There has been good news and bad news for Centene (CNC 2.80%) this year. The health insurer reported strong second-quarter results in July. But its share price has dropped like a brick throughout much of 2019. 

The company announced its third-quarter results before the market opened on Tuesday. This time, there was plenty of good news for investors. Here are the highlights from Centene's Q3 update.

Hand holding jigsaw puzzle piece with Medicaid printed on it

Image source: Getty Images.

By the numbers

Revenue jumped 17% year over year in the third quarter to almost $19 billion. Analysts estimated that the company's revenue for the third quarter would come in at $18.4 billion.

The company posted net income in the third quarter of $95 million, or $0.26 per share, based on generally accepted accounting principles (GAAP). This was a major improvement upon Centene's result in the prior-year period, when the company announced GAAP net income of $19 million, or $0.05 per share.

Centene announced Q3 adjusted net income of $0.96 per share, compared with $0.89 per share in the same period in 2018. This narrowly beat the average analysts' earnings estimate of $0.95 per share.

Behind the numbers

The steady rise in revenue stemmed in large part from growth in the Health Insurance Marketplace business. This included new programs in states including Arkansas, Illinois, Iowa, New Mexico, and Pennsylvania. In addition, Centene's review increased from its recent acquisition of Spanish healthcare company Ribera Salud.

Centene's bottom-line improvement looked even better than its revenue growth for a simple reason: Costs rose more slowly than revenue did. One big factor was that the company spent significantly less on selling, general, and administrative expenses than it did in the prior-year period.

Other notable developments for Centene subsequent to the end of the third quarter included:

  • The company's board of directors approved a $500 million increase to its stock buyback program.
  • Centene, Walgreens Boots Alliance, and RxAdvance announced a partnership to launch a new model for pharmacy management.
  • Carolina Complete Health, Centene's joint venture in North Carolina, received an additional Medicaid managed care services region. This brings the total number of regions served by Carolina Complete Health to three, with the new contract scheduled to take effect in February 2020.

Looking ahead

Centene anticipates revenue to come in between $73.6 billion and $74.2 billion in full-year 2019. The company also projects 2019 adjusted earnings per share will be between $4.29 and $4.49.

CEO Michael Neidorff stated that Centene will continue to "further enhance our leadership position in government-sponsored healthcare." One key part of making that happen is the company's pending merger with WellCare Health Plans.

Any investor who follows healthcare stocks knows that such big deals can run into roadblocks with regulators. But Centene should be helped by a deal where Anthem will buy WellCare's Medicaid plans in Missouri and Nebraska. This divestiture should help clear the way for Centene's merger with Wellcare.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Centene Corporation Stock Quote
Centene Corporation
$96.64 (2.80%) $2.63
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
$40.59 (1.30%) $0.52
WellCare Health Plans, Inc. Stock Quote
WellCare Health Plans, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.